ASCO 2022 | Lymphoma at ASCO 2022: SHINE, ECHELON-1
Tycel Phillips, MD, University of Michigan, Ann Arbor, MI, discusses key updates in lymphoma presented at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the Phase III SHINE study (NCT01776840) of ibrutinib in combination with bendamustine and rituximab in elderly patients with newly diagnosed mantle cell lymphoma (MCL). Dr Phillips also talks on the long-term follow-up results of ECHELON-1 (NCT01712490) which assessed the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical Hodgkin lymphoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
